Nalaganje...
Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date
Immunotherapy with immune checkpoint inhibitors has opened a new arena in cancer therapeutics. Pembrolizumab is a highly selective anti-programmed cell death protein 1 (PD-1) antibody that has shown efficacy, leading to survival benefit and durable responses, in some patients with non-small cell lun...
Shranjeno v:
| izdano v: | Onco Targets Ther |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove Medical Press
2016
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5045223/ https://ncbi.nlm.nih.gov/pubmed/27713639 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S97746 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|